Novocure Reports Third Quarter 2022 Financial Results

Novocure (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022.

Quarterly net revenues of $131 million with $52 million invested in research & development initiatives

Entering a transformational period with multiple pivotal trial readouts anticipated in coming quarters

ROOT, Switzerland--(BUSINESS WIRE)--NovoCure Ltd. (NASDAQ: NVCR) today reported financial results for the quarter ended September 30, 2022. Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer by developing and commercializing its innovative therapy, Tumor Treating Fields (TTFields).

“In the third quarter, we showed consistent execution in service of our mission to extend survival in some of the most aggressive forms of cancer,” said William Doyle, Novocure’s Executive Chairman. “We are diligently working to reach additional patients in our current markets, expand into new markets, enhance our products and treat patients in new indications throughout the body. We are investing aggressively to prepare Novocure for the future and are eager to treat many more patients in the coming years.”

“Novocure is approaching a period that should be transformational for our company and patients,” said Asaf Danziger, Novocure’s Chief Executive Officer. “January marks the beginning of a two-year period of multiple data releases from our pivotal studies exploring the use of TTFields in a variety of solid tumor cancers and combinations. These data catalysts could enable us to treat tens of thousands more patients in the future, and we look forward to sharing these results with physicians, patients, and the investor community in the coming quarters.”

Financial updates for the third quarter ended September 30, 2022:

  • Total net revenues for the quarter were $131.0 million, a decrease of 2% compared to the same period in 2021.
    • The United States, EMEA and Japan contributed $102.7 million, $14.3 million, and $7.9 million in quarterly net revenues, respectively.
    • Net revenues were impacted by the volume of cash collections from aged claims in the U.S., the ongoing impact of German coverage updates and foreign exchange pressure.
    • Revenue in Greater China from Novocure’s partnership with Zai Lab totaled $6.2 million.
  • Gross margin for the quarter was 77%.
  • Research, development and clinical studies expenses for the quarter were $52.0 million, an increase of 8% from the same period in 2021.
  • Sales and marketing expenses for the quarter were $41.4 million, an increase of 27% compared to the same period in 2021. This reflects increased investments in early commercial and market access capabilities.
  • General and administrative expenses for the quarter were $32.5 million, an increase of 4% compared to the same period in 2021.
  • Net loss for the quarter was $26.6 million with loss per share of $0.25.
  • Adjusted EBITDA* for the quarter was $4.4 million.
  • Cash, cash equivalents and short-term investments were $970.3 million as of September 30, 2022.

Operational updates for the third quarter ended September 30, 2022:

  • As of September 30, 2022, there were 3,420 active patients on therapy. Active patients from North America, EMEA and Japan contributed 2,181, 885 and 354 active patients, respectively.
  • 1,389 prescriptions were received in the quarter. Prescriptions from North America, EMEA and Japan contributed 978, 332 and 79 prescriptions, respectively.

Quarterly updates and achievements:

  • Today, we are announcing preliminary data from the phase 2 EF-33 pilot study evaluating the safety and efficacy of high density arrays in 25 patients with recurrent glioblastoma (GBM). Among those who used Optune® as directed for at least one month, median progression-free survival was 4.5 months compared to 2.2 months in the historical control, Novocure’s pivotal EF-11 study. Further, notwithstanding the increased TTFields intensity, EF-33 patients reported no TTFields-related toxicity.
  • Our phase 3 pivotal METIS study for the treatment of brain metastases from non-small cell lung cancer (NSCLC) continues to enroll well, and we have visibility to final patient enrollment; however, we now expect to complete enrollment in the first quarter of 2023 versus the fourth quarter of 2022. This will begin the final patient’s 12-month follow-up period, and we anticipate top-line data in the first quarter of 2024.
  • In September 2022, we announced the creation of our U.S. CNS (central nervous system) Cancers Franchise, intended to strengthen focus on growth in our U.S. GBM business by streamlining decision-making and improving coordination.

Anticipated clinical milestones:

  • Top-line readout from phase 3 pivotal LUNAR study in NSCLC cancer (Q1 2023)
  • Data from phase 3 pivotal INNOVATE-3 study in recurrent ovarian cancer (2023)
  • Data from phase 3 pivotal METIS study in brain metastases (2024)
  • Data from phase 3 pivotal PANOVA-3 study in locally advanced pancreatic cancer (2024)

Conference call details

Novocure will host a conference call and webcast to discuss third quarter 2022 financial results at 8 a.m. EDT today, Thursday, October 27, 2022. Analysts and investors can participate in the conference call by using the following registration link, and dial-in details will be provided.

The webcast, earnings slides presented during the webcast and the corporate presentation can be accessed live from the Investor Relations page of Novocure’s website, www.novocure.com/investor-relations, and will be available for at least 14 days following the call. Novocure has used, and intends to continue to use, its investor relations website, as a means of disclosing material non-public information and for complying with its disclosure obligations under Regulation FD.

About Novocure

Novocure is a global oncology company working to extend survival in some of the most aggressive forms of cancer through the development and commercialization of its innovative therapy, Tumor Treating Fields. Novocure’s commercialized products are approved in certain countries for the treatment of adult patients with glioblastoma and malignant pleural mesothelioma. Novocure has ongoing or completed clinical studies investigating Tumor Treating Fields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer and ovarian cancer.

Headquartered in Root, Switzerland and with a growing global footprint, Novocure has regional operating centers in Portsmouth, New Hampshire and Tokyo, as well as a research center in Haifa, Israel. For additional information about the company, please visit Novocure.com and follow @Novocure on LinkedIn and Twitter.

*Non-GAAP Financial Measurements

We measure our performance based upon a non-U.S. GAAP measurement of earnings before interest, taxes, depreciation, amortization and shared-based compensation (“Adjusted EBITDA”). We believe Adjusted EBITDA is useful to investors in evaluating our operating performance because it helps investors compare the results of our operations from period to period by removing the impact of earnings attributable to our capital structure, tax rate and material non-cash items, specifically share-based compensation.

Forward-Looking Statements

In addition to historical facts or statements of current condition, this press release may contain forward-looking statements. Forward-looking statements provide Novocure’s current expectations or forecasts of future events. These may include statements regarding anticipated scientific progress on its research programs, clinical study progress, development of potential products, interpretation of clinical results, prospects for regulatory approval, manufacturing development and capabilities, market prospects for its products, coverage, collections from third-party payers and other statements regarding matters that are not historical facts. You may identify some of these forward-looking statements by the use of words in the statements such as “anticipate,” “estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other words and terms of similar meaning. Novocure’s performance and financial results could differ materially from those reflected in these forward-looking statements due to general financial, economic, environmental, regulatory and political conditions as well as issues arising from the COVID-19 pandemic and other more specific risks and uncertainties facing Novocure such as those set forth in its Annual Report on Form 10-K filed on February 24, 2022, and subsequent filings with the U.S. Securities and Exchange Commission. Given these risks and uncertainties, any or all of these forward-looking statements may prove to be incorrect. Therefore, you should not rely on any such factors or forward-looking statements. Furthermore, Novocure does not intend to update publicly any forward-looking statement, except as required by law. Any forward-looking statements herein speak only as of the date hereof. The Private Securities Litigation Reform Act of 1995 permits this discussion.

Consolidated Statements of Operations

USD in thousands (except share and per share data)

Three months ended

September 30,

Nine months ended

September 30,

Year ended

December 31,

2022

2021

2022

2021

2021

Unaudited

Unaudited

Audited

Net revenues

$

130,998

$

133,606

$

409,411

$

401,818

$

535,031

Cost of revenues

29,749

30,206

85,979

85,190

114,877

Gross profit

101,249

103,400

323,432

316,628

420,154

Operating costs and expenses:

Research, development and clinical studies

51,956

48,141

151,265

144,372

201,303

Sales and marketing

41,395

32,580

124,029

98,075

137,057

General and administrative

32,509

31,231

94,683

95,116

126,127

Total operating costs and expenses

125,860

111,952

369,977

337,563

464,487

Operating income (loss)

(24,611

)

(8,552

)

(46,545

)

(20,935

)

(44,333

)

Financial expenses (income), net

(1,194

)

1,981

2,743

5,567

7,742

Income (loss) before income taxes

(23,417

)

(10,533

)

(49,288

)

(26,502

)

(52,075

)

Income taxes

3,159

2,591

5,943

5,391

6,276

Net income (loss)

$

(26,576

)

$

(13,124

)

$

(55,231

)

$

(31,893

)

$

(58,351

)

Basic net income (loss) per ordinary share

$

(0.25

)

$

(0.13

)

$

(0.53

)

$

(0.31

)

$

(0.56

)

Weighted average number of ordinary shares used in computing basic net income (loss) per share

104,884,583

103,731,147

104,552,803

103,281,380

103,433,274

Diluted net income (loss) per ordinary share

$

(0.25

)

$

(0.13

)

$

(0.53

)

$

(0.31

)

$

(0.56

)

Weighted average number of ordinary shares used in computing diluted net income (loss) per share

104,884,583

103,731,147

104,552,803

103,281,380

103,433,274

Consolidated Balance Sheets

USD in thousands (except share data)

September 30,

2022

December 31,

2021

Unaudited

Audited

ASSETS

CURRENT ASSETS:

Cash and cash equivalents

$

243,805

$

208,802

Short-term investments

726,515

728,898

Restricted cash

231

807

Trade receivables, net

87,552

93,567

Receivables and prepaid expenses

17,478

17,025

Inventories

26,792

24,427

Total current assets

1,102,373

1,073,526

LONG-TERM ASSETS:

Property and equipment, net

29,745

22,693

Field equipment, net

11,985

12,923

Right-of-use assets

19,405

18,267

Other long-term assets

10,707

12,086

Total long-term assets

71,842

65,969

TOTAL ASSETS

$

1,174,215

$

1,139,495

Consolidated Balance Sheets

USD in thousands (except share data)

September 30,

2022

December 31,

2021

Unaudited

Audited

LIABILITIES AND SHAREHOLDERS’ EQUITY

CURRENT LIABILITIES:

Trade payables

$

77,026

$

72,600

Other payables, lease liabilities and accrued expenses

64,050

70,002

Total current liabilities

141,076

142,602

LONG-TERM LIABILITIES:

Long-term debt, net

564,677

562,216

Deferred revenue

3,924

6,477

Long-term leases

14,827

12,997

Employee benefit liabilities

4,088

4,543

Other long-term liabilities

222

166

Total long-term liabilities

587,738

586,399

TOTAL LIABILITIES

728,814

729,001

COMMITMENTS AND CONTINGENCIES

SHAREHOLDERS’ EQUITY:

Share capital -

Ordinary shares no par value, unlimited shares authorized; issued and outstanding:

104,942,941 shares and 103,971,263 shares at September 30, 2022 (unaudited) and December 31, 2021, respectively

Additional paid-in capital

1,188,864

1,099,589

Accumulated other comprehensive income (loss)

(2,306

)

(3,169

)

Retained earnings (accumulated deficit)

(741,157

)

(685,926

)

TOTAL SHAREHOLDERS’ EQUITY

445,401

410,494

TOTAL LIABILITIES AND SHAREHOLDERS’ EQUITY

$

1,174,215

$

1,139,495

Non-U.S. GAAP financial measures reconciliation

USD in thousands

Three months ended September 30,

Nine months ended September 30,

2022

2021

% Change

2022

2021

% Change

Net income (loss)

$

(26,576

)

$

(13,124

)

102

%

$

(55,231

)

$

(31,893

)

73

%

Add: Income tax

3,159

2,591

22

%

5,943

5,391

10

%

Add: Financial expenses (income), net

(1,194

)

1,981

(160

) %

2,743

5,567

(51

) %

Add: Depreciation and amortization

2,659

2,734

(3

) %

7,924

7,584

4

%

EBITDA

$

(21,952

)

$

(5,818

)

277

%

$

(38,621

)

$

(13,351

)

189

%

Add: Share-based compensation

26,305

25,758

2

%

77,173

72,502

6

%

Adjusted EBITDA

$

4,353

$

19,940

(78

) %

$

38,552

$

59,151

(35

) %

Contacts

Investors:
Ingrid Goldberg
investorinfo@novocure.com
610-723-7427

Media:
Leigh Labrie
media@novocure.com
610-723-7428

Source: Novocure

MORE ON THIS TOPIC